Health developments span infectious disease monitoring, ophthalmology breakthroughs, rare disease funding expansion, and metabolic treatment advances

The CDC reports hantavirus risk to the general US public remains very low, with over 100 staff members actively monitoring the situation to ensure public safety.

Three emerging treatments for dry eye disease show promising potential at the ARVO 2026 Annual Meeting, offering new hope for patients with this common condition.

EyePoint Pharmaceuticals' experimental eye disease drug Duravyu advanced in late-stage trials after an independent safety panel found no new safety concerns and recommended continuation.

The UK's NICE approved routine NHS funding for nusinersen and risdiplam treatments for spinal muscular atrophy, ending time-limited managed access schemes that had been in place since 2019.

Orforglipron demonstrated maintained weight loss benefits in obesity patients, highlighting that continued medication therapy is essential for sustained treatment outcomes regardless of delivery method changes.

Empagliflozin and dapagliflozin SGLT2 inhibitors showed comparable effectiveness in preventing cardiorenal complications among type 2 diabetes patients without prior cardiovascular or kidney disease.

In-office nitrous oxide use for obstetric and gynecological procedures reduced operating room burden, associated costs, and provided greater patient convenience compared to traditional surgical settings.

Adolescent sleep patterns are significantly influenced by stress levels and neighborhood support, with higher stress linked to irregular sleep and supportive communities associated with more stable sleep schedules.